Tuesday - November 8, 2016
IRST IRCCS, Meldola
Welcome and introduction
Presidents: Dino Amadori, Giovanni Luca Frassineti (Meldola, Italy)
Chairman: Stefano Cascinu (Modena, Italy)
Marc E. Lippman
Miami, USA
The evolution of translational medicine
Giovanni Paganelli
Meldola, Italy
The Avidin-Biotin pretargeting system for molecular radiotherapy in cancer patients
Nelson Chao
Durham, USA
Health global project
Nestory Masalu
Mwanza, Tanzania
Collaboration Bugando-IRST: ongoing projects
Thomas Ladd
Jacksonville, USA
Radiating Hope - advancing cancer care in developing countries
Wednesday - November 9, 2016
Globus Hotel - Forlì
NEO ANGIOGENESIS
President: Alfredo Falcone (Pisa, Italy)
Chairmen: Giampietro Gasparini (Bari, Italy), Davide Tassinari (Rimini, Italy)
Romano Danesi
Pisa, Italy
Resistance and escape from antiangiogenic therapy
Daniele Generali
Trieste, Italy
Biomolecular predictive factors of response: lights and shade
Riccardo Giampieri
Ancona, Italy
Antiangiogenic therapy in GI cancer: current status and future directions
ANTI-HER2 THERAPIES
President: Marc E. Lippman (Miami, USA)
Chairmen: Lorenzo Gianni (Rimini, Italy), Andrea Rocca (Meldola, Italy)
Mattia Lauriola
Bologna, Italy
HER receptor family and pathways:
a systems biology perspective
Javier Cortes
Barcelona, Spain
New anti-HER2 molecules: monoclonal antibodies,
antibody-drug conjugates, small molecule TKIs
Geraldine Gebhart
Brussels, Belgium
The contribution of molecular imaging to investigate tumor heterogeneity and early evaluation of response
to anti-HER2 agents in Breast Cancer
NEW INSIGHTS INTO INHIBITION PATHWAYS
President: Gerardo Musuraca (Meldola, Italy)
Chairmen: Francesco Lanza (Ravenna, Italy), Patrizia Tosi (Rimini, Italy)
Gianluca Gaidano
Novara, Italy
PI3K inhibition
Lapo Alinari
Columbus, USA
Targeting BTK
Nicola Fazio
Milano, Italy
The world of mTOR
Giovanni Martinelli
Bologna, Italy
The anti apoptosis way in cancer: BCL2 inhibition
Luca Malorni
Prato, Italy
Cell cycle checkpoints (CDK4/6) inhibitors
Vanda Salutari
Roma, Italy
Update on PARP inhibitors:
opportunities and challeneges in cancer therapy
Thursday - November 10, 2016
Globus Hotel (Forlì)
CELL THERAPIES
President: Massimo Guidoboni (Meldola, Italy)
Chairmen: Massimiliano Bonafè (Bologna, Italy), Carl Figdor (Nijmegen, The Netherlands)
Nelson Chao
Durham, USA
Tumor immunology with emphasis on MDSCs
Massimo Guidoboni
Meldola, Italy
Adoptive T cell therapies: new tricks from old dogs?
Carl Figdor
Nijmegen, The Netherlands
Dendritic cell-based cancer immunotherapy
Franco Locatelli
Roma, Italy
CAR-T cells: chimera or reality?
IMMUNOTHERAPY
President: Angelo Delmonte (Meldola, Italy)
Chairmen: Francesco Di Costanzo (Firenze, Italy), Ruggero Ridolfi (Forlì, Italy)
Federico Cappuzzo
Ravenna, Italy
PD1/PDL1 axis in solid tumors
Luana Calabrò
Siena, Italy
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
ANTI EGFR
President: Daniele Calistri (Meldola, Italy)
Chairmen: Luigi Cavanna (Piacenza, Italy), Paola Ulivi (Meldola, Italy)
Lucio Crinò
Meldola, Italy
First generation anti-EGFR therapies and resistance
mechanisms
Vanesa Gregorc
Milano, Italy
New drugs bypassing the anti-EGFR blockade
Nicola Normanno
Napoli, Italy
Clonal evolution in response to anti-EGFR therapies
HORMONAL RECEPTORS
President: Vincenza Conteduca (Meldola, Italy)
Chairmen: Laura Amaducci (Faenza, Italy), Valentina Arcangeli (Rimini, Italy)
Alessandra Gennari
Genova, Italy
Predicting response to endocrine therapies in breast cancer
Elisabetta Pietri
Meldola, Italy
The role of androgen receptors in breast cancer
Himisha Beltran
New York, USA
Mechanisms of resistance and neuroendocrine differentiation in prostate cancer
Michal Mego
Bratislava, Slovakia
Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer
Friday November 11, 2016
Globus Hotel - Forlì
NEW PERSPECTIVES FOR PRECISION MEDICINE
President: Toni Ibrahim (Meldola, Italy)
Chairman: Laura Mercatali (Meldola, Italy)
Gabri Van der Pluijm
Leiden, The Netherlands
Near patient models for the assessment of tumor aggressiveness
Daniele Santini
Roma, Italy
New horizons on bone targeted therapies
Maria Abbondanza Pantaleo
Bologna, Italy
Histotype or molecular driven treatment of sarcomas?
Nerina Denaro
Cuneo, Italy
Role of immunotherapy in virus related head and neck cancer
RADIONUCLIDE THERAPY AND ALLIED SCIENCE
President: Giovanni Paganelli (Meldola, Italy)
Chairmen: Domenico Barone (Meldola, Italy), Muller Fabbri (Los Angeles, USA), Maria Salvato (Baltimore, USA)
Stefano Severi
Meldola, Italy
A new proposal for a metabolic classification of NENS
Bernard Van Beers
Paris, France
Imaging biomarkers in oncologic liver disease
Muller Fabbri
Los Angeles, USA
Exosomic microRNAs orchestrate cancer biology and resistance to chemotherapy
Presentation of the Best Abstracts
Chairmen: Dino Amadori, Giovanni Luca Frassineti (Meldola, Italy)
Paola Ulivi
Role of TP53 mutations in determining primary resistance to first-line tyrosine kinase inhibitors in EGFRmutated NSCLC patients
Giorgia Gurioli
Circulating tumor cells as liquid biopsy for castration resistant prostate cancer (CRPC) patients treated with cabazitaxel
Francesca Salamanna
An in vitro 3D bone metastasis model by using a human bone tissue culture and human sex-related cancer cells
Poster
